Takehisa Ueno

Takehisa Ueno

Auto-generated profile, based on publicly available information

Takehisa Ueno

Department of Pediatric Surgery Osaka University Graduate School of Medicine Suita Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2018 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
TUTakehisa Ueno
Takehisa Ueno
TKTasuku Kodama
Tasuku Kodama
YNYuki Noguchi
Yuki Noguchi
RSRyuta Saka
Ryuta Saka
YTYuichi Takama
Yuichi Takama
HOHiroomi Okuyama
Hiroomi Okuyama

29 March 2011 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
TUTakehisa Ueno
Takehisa Ueno
NTNatsumi Tanaka
Natsumi Tanaka
YIYoshiyuki Ihara
Yoshiyuki Ihara
YTYuichi Takama
Yuichi Takama
HYHiroyuki Yamada
Hiroyuki Yamada
MFMasahiro Fukuzawa
Masahiro Fukuzawa

4 September 2017 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
TUTakehisa Ueno
Takehisa Ueno
RSRyuta Saka
Ryuta Saka
YTYuichi Takama
Yuichi Takama
HYHiroaki Yamanaka
Hiroaki Yamanaka
YTYuko Tazuke
Yuko Tazuke
HOHiroomi Okuyama
Hiroomi Okuyama

10 March 2016 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
TUTakehisa Ueno
Takehisa Ueno
SUShuichiro Uehara
Shuichiro Uehara
KNKengo Nakahata
Kengo Nakahata
HOHiroomi Okuyama
Hiroomi Okuyama
Survivin, a member of the inhibitor of apoptosis protein family, functions as a key regulator of programmed cell death. YM155 is a small molecule that selectively inhibits survivin. We investigated the effect of YM155 on survivin suppression in the human rhabdomyosarcoma (RMS) cell line RD. The efficacy of YM155 in combination with cisplatin was also determined in a xenograft model. The effect of YM155 on survivin expression in the RD cell line was examined at both mRNA and protein levels using real-time PCR and western blot analysis. RD cells were cultured with various concentrations of YM155, then cisplatin was added to the medium and the anti-proliferation response was determined. Cell growth was evaluated by WST-8 assay. Finally, the efficacy of YM155 combined with cisplatin was examined in an established xenograft model. Survivin mRNA levels in the RD cell line were decreased to 72 and 24% at 24 and 48 h, respectively, after 10 nM of YM155 was added. YM155 also decreased the levels of survivin protein. YM155 treatment (10 nM) inhibited cell proliferation of RD in a dose-dependent manner in vitro, with 58% of cells viable at 48 h. When cultured with 10 nM of YM155 and 10 µM cisplatin, RD cells demonstrated only 25% of the growth observed when cultured with cisplatin alone. YM155 in combination with cisplatin significantly inhibited tumor growth by 13% compared with control (P<0.0001) in RD xenograft tumors. YM155 increased the sensitivity of cisplatin by suppressing survivin in the embryonal RMS cell line RD. Further studies should investigate the use of YM155 as an apoptosis inducer, either alone or in combination with cisplatin, for the treatment of malignant RMS.

1 June 2013 in Transplantation Proceedings
Verified
Journal Article
Closed access
TUT. Ueno
T. Ueno
MWM. Wada
M. Wada
KHK. Hoshino
K. Hoshino
SSS. Sakamoto
S. Sakamoto
HFH. Furukawa
H. Furukawa
MFM. Fukuzawa
M. Fukuzawa

1 May 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
TUT. Ueno
T. Ueno
MZM. Zenitani
M. Zenitani
HYH. Yamanaka
H. Yamanaka
NTN. Tanaka
N. Tanaka
SUS. Uehara
S. Uehara
HOH. Okuyama
H. Okuyama